Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07349537 · ClinicalTrials.gov registry record · Phase 1
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
A Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors, sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 574
- Enrollment target
- 5
- Study locations
NCT07349537 is a Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 574 participants, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (47% higher). The trial reports 5 study locations across 3 states.
The verdict
NCT07349537, a Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors, is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 574 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
Conditions Studied
Interventions
- DRUG RMC-5127
- DRUG daraxonrasib
- DRUG cetuximab
Study Locations (5)
Texas
- NEXT - Dallas - Dallas
- NEXT - San Antonio
- START - San Antonio - San Antonio
Michigan
- START Midwest - Grand Rapids
Virginia
- NEXT - Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 574 participants |
| Start Date | 2026-01-08 |
| Est. Completion | 2028-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07349537
The ClinicalTrials.gov registry entry for NCT07349537 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 574 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (47% higher). The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which RMC-5127 is the first listed.
NCT07349537 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Texas, Michigan, Virginia.
Frequently Asked Questions
What is clinical trial NCT07349537 about?
NCT07349537 is a clinical study titled "Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
What is the current status of trial NCT07349537?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 574 participants. The study started on 2026-01-08. Estimated completion is 2028-10.
What conditions does trial NCT07349537 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Advanced Solid Tumors, NSCLC, Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT07349537?
The interventions under investigation include: RMC-5127 (DRUG), daraxonrasib (DRUG), cetuximab (DRUG).
Who is sponsoring clinical trial NCT07349537?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07349537 being conducted?
This trial has 5 study locations across Michigan, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.